U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07142642) titled 'A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants' on Aug. 25.
Brief Summary: The primary objective of the study is to evaluate the pharmacokinetics (PK) of teprotumumab after a single intravenous (IV) infusion of teprotumumab in healthy Chinese participants.
Study Start Date: Aug. 30
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers
Intervention:
DRUG: Teprotumumab
Administered via IV infusion.
DRUG: Placebo
Administered via IV infusion.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Amgen
Published by HT Digital Co...